Latest News - Johnson & Johnson

Top Corporates Hub

Johnson & Johnson

JNJ | NYSE | United States
27
Rank
$350.63B
Market Cap
$88.82B
Revenue
$17.44B
+$ 3.37B
+23.95%
Earnings
138.1K
+8.1K
+6.23%
Employees
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down

20.11.2026 14:10

Halozyme faces a legal setback in Germany as a court overturns an injunction against Merck's Keytruda SC, prompting a new patent lawsuit.

Read More

Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness

20.11.2026 13:00

Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). TREMFYA met primary and major secondary endpoints that demonstrated significant improvement in axial symptoms compared to placebo and significant reduction of MRI-assessed inflammation in the sacroiliac joints.1,a The Phase 4 STAR study is the first and only dedicated randomized, double-b

Read More

3 ETFs That Give You Johnson & Johnson In Different Doses

20.11.2026 12:11

You might like Johnson & Johnson for its mix of medicine and medical devices, but owning a single stock means living with its specific risks. Simply Wall St flags pressure on profit margins, with recent margins at 16.2% versus 27.2% last year. Holding Johnson & Johnson inside a fund spreads that business specific hit across many holdings, and also spreads out any gains. On 19 November 2026, Johnson & Johnson reported the first commercial installation of its new robotic surgery system at...

Read More

ETFs Are Net Sellers of Johnson & Johnson (JNJ) on Wednesday

20.11.2026 11:03

ETFs sold a net $144.2 million of Johnson & Johnson on Wednesday, Nov. 18.

Read More

AbbVie Is Near Its High. Piper Sandler Sees Another 23%

20.11.2026 09:37

Key TakeawaysPiper Sandler raised its AbbVie price target to $349 from $303 and kept its Overweight rating, 23% above the Nov. 19 close of $283.

Read More

Johnson & Johnson’s Phase 4 STAR Study Of TREMFYA Meets Met Primary And Major Secondary Endpoints In Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement

20.11.2026 09:02

TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 studyTREMFYA

Read More

Stock Screening Made Simple: A Closer Look

20.11.2026 00:08

Stock screening is commonly deployed by investors to 'cut through the noise.' The approach is especially useful when you're choosing from thousands of options, which can often overwhelm investors.

Read More

Should Biogen Stock Holders Look At Amgen Instead?

19.11.2026 11:30

Today's big story: Could Anthropic Stock Fall 25.

Read More

What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 17

19.11.2026 11:05

The fund cut all 60 of its positions, selling $250.1 million of stock, led by Eli Lilly at $42.3 million.

Read More

Global Multiport Surgical Robot Market 2026 Report: Trends and Forecast to 2030 | Capitalize on 19.1% CAGR as Intuitive Surgical, Medtronic, J&J and CMR Surgical Advance AI Surgery

18.11.2026 14:57

Boost ROI with telesurgery and AI-assisted platforms, localized manufacturing to curb tariff costs, and acquisitions that expand product portfolios and global reach.Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Multiport Surgical Robot Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global multiport surgical robot market is experiencing rapid growth as healthcare providers expand the use of robotic-assisted and minimally invasive surgery. The market is projected to incr

Read More

Global Abdominal Surgical Robot Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.9% CAGR as Intuitive Surgical, Medtronic, J&J, and CMR Surgical Advance AI

18.11.2026 14:56

Boost ROI through AI sensing, 3D visualization, force feedback and modular platforms; use acquisitions, local assembly and regional suppliers to cut costs and improve workflows.Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Abdominal Surgical Robot Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global abdominal surgical robot market is experiencing rapid growth as healthcare providers expand their use of robotic-assisted, minimally invasive procedures. The market is pro

Read More

Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK

18.11.2026 14:35

Boost ROI with AI analytics, decentralized monitoring, EDC, stronger patient recruitment and retention, expanded lab capacity, and rigorous compliance.Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Allergy Clinical Trial Services Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global allergy clinical trial services market is experiencing strong growth as pharmaceutical and biotechnology companies increase investment in research for allergic diseases. The market is

Read More

SLS And IBRX Share 3 Institutional Backers With Big Pharma Giants — As Stanley Druckenmiller Makes Bold Prediction: ‘We’re Gonna Beat Cancer’

18.11.2026 08:31

New York’s pension fund held $1.42 billion in the three pharma giants versus just under $2 million in SLS and IBRX.

Read More

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue

17.11.2026 11:45

Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.

Read More

The Zacks Analyst Blog Highlights Taiwan, Johnson & Johnson, Palantir, Title and Altigen

17.11.2026 10:08

Taiwan, Johnson & Johnson, Palantir, Title and Altigen are included in this Analyst Blog.

Read More

J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports

16.11.2026 01:23

Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.

Read More

3 Biotech Stocks With Revenue Up To 11%

14.11.2026 06:15

AI related risks just jumped to the top of the Federal Reserve’s financial stability worries, with a surge in complex debt tied to AI infrastructure. That kind of boom and scrutiny can push investors to look at other cutting edge areas. Carefully chosen biotech stocks with solid balance sheets can offer a different source of potential high upside. This article walks through three such biotech opportunities from our US screener. The three biotech stocks covered below are only a small sample...

Read More

Could You Have Held Glaukos Stock Through Its Falls?

14.11.2026 01:08

For questions about this article or underlying research, email help@trefis.com.

Read More

4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%

13.11.2026 20:47

A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that grows, and the gap between them is wider than it looks.

Read More